JS-10 phantom. by Masakazu Tsujimoto (22339504)

“…At ≥50 s/view, variation in the maximum and mean SUVs decreased, with the RSE remaining below 5%. In conclusion, accurate SUV measurement with ¹²³I-MIBG requires an acquisition time of ≥50 s/view, an SI product of approximately 120, and a Gaussian filter of 10 − 12 mm. …”

The raw data used for the analyses in this study. by Masakazu Tsujimoto (22339504)

“…At ≥50 s/view, variation in the maximum and mean SUVs decreased, with the RSE remaining below 5%. In conclusion, accurate SUV measurement with ¹²³I-MIBG requires an acquisition time of ≥50 s/view, an SI product of approximately 120, and a Gaussian filter of 10 − 12 mm. …”

Changes associated with kidney fibrosis in TGF- by Wencheng Jin (13136262)

Validation of MN705 treatment effects in human proximal tubular epithelial cells during TGF- by Wencheng Jin (13136262)

Microtubules and Lis-1/NudE/Dynein Regulate Invasive Cell-on-Cell Migration in Drosophila by Nachen Yang (151862)

“…A screen of 67 genes encoding microtubule interacting proteins uncovered cell autonomous requirements for Lis-1, NudE and Dynein in border cell migration. Net cluster migration was decreased, with initiation of migration and formation of dominant front cell protrusion being most dramatically affected. …”

Binding and function of nAbs on Aβ_1–42. by Alexandra Albus (3325170)

“…Aβ_1–42 oligomers were dotted in a decreasing concentration pattern, and the membrane was further incubated in nAbs-solution. …”

Effect of MN705 treatment on TGF- by Wencheng Jin (13136262)

Expression of cytokines by CD3+ infiltration in PDAC. by Gerik W. Tushoski-Alemán (17951809)

“…(D) Principal component analysis plot of inflammatory signatures in different tissues, PCA was performed using 31 analytes, as 10 analytes (G-CSF, IL-9,IL-1B,IL-2,IL-3,IL-4,IL-5,MIP-1A,RANTES and TNFB) had limited detection across our patient cohort. …”

Expression of cytokines by CD8+ infiltration in PDAC. by Gerik W. Tushoski-Alemán (17951809)

“…(C) Principal component analysis plot of inflammatory signatures in different tissues, PCA was performed using 31 analytes, as 10 analytes (G-CSF, IL-9,IL-1B,IL-2,IL-3,IL-4,IL-5,MIP-1A,RANTES and TNFB) had limited detection across our patient cohort. …”

Data Sheet 1_DYRK1A roles in human neural progenitors.docx by Jeremie Courraud (20871932)

“…In addition, DYRK1A-KD led to a reduction in p21 protein levels, despite an increase in the expression of a minor transcript variant for this gene, and a decrease in ERK pathway activation.…”

The screening process of MN705. by Wencheng Jin (13136262)

Quantification of intratumoral CD3+ and CD8+ lymphocytes. by Gerik W. Tushoski-Alemán (17951809)

Effect of HCQ on T cell activation markers post stimulation with 8μg/mL HPV (human papilloma virus) peptide pool. by Monika M. Kowatsch (11722292)

Changes associated with kidney fibrosis and effects of MN705 treatment on TGF- by Wencheng Jin (13136262)

Effect of HCQ on T cell subsets from <i>ex vivo</i> PBMCs. by Monika M. Kowatsch (11722292)

Effect of HCQ on T cell activation markers post stimulation with 2μg/mL CEF (cytomegalovirus, Epstein Barr virus, and influenza virus) peptide pool. by Monika M. Kowatsch (11722292)

Analysis of color parameters (<i>L</i>, <i>a</i>, <i>b</i>*) and color difference (Δ<i>E</i>*_<i>ab</i>) values^a before and after hypoxic stress in cherry shri... by Wei-Wei Hou (3405947)

Downregulating lncRNA <i>CASC9</i> in SW620 xenograft tumor inhibits SW620 proliferation. by Heping Zhang (29038)

Dynamic Tracking of <i>In Vivo</i> Receptor Availability in Tumor Using Paired-Agent Imaging by Yichen Feng (450964)

“…These results demonstrate PAI as a simple imaging strategy that could allow dose optimization in pharmaceutical development and patient-specific dosing for molecular therapeutics.…”

Dynamic Tracking of <i>In Vivo</i> Receptor Availability in Tumor Using Paired-Agent Imaging by Yichen Feng (450964)

“…These results demonstrate PAI as a simple imaging strategy that could allow dose optimization in pharmaceutical development and patient-specific dosing for molecular therapeutics.…”